Tumour-promoting inflammation is considered one of the enabling characteristics of cancer
development. Chronic inflammatory disease increases the risk of some cancers, and strong …

Immunotherapy has markedly improved treatment outcomes in rheumatoid arthritis (RA).
Tumor necrosis factor (TNF)‑α antagonists, such as infliximab (IFX), etanercept (ETN) …

Context Concerns exist regarding the potential development of malignancies in patients with
rheumatoid arthritis (RA) who are receiving biologic response modifiers (BRMs). Objective …

Antibodies are well established in mainstream clinical practice and present an exciting area
for collaborative research and development in industry and academia alike. In this review …

Cancers harbor significant genetic heterogeneity and patterns of relapse following many
therapies are due to evolved resistance to treatment. While efforts have been made to …

Patients with rheumatoid arthritis (RA) have a greater risk of developing both Hodgkin
lymphoma (HL) and non‐HL than the general population. Non‐Hodgkin lymphoma is more …

Cytokines are the key mediators of inflammation in the course of autoimmune arthritis and
other immune-mediated diseases. Uncontrolled production of the pro-inflammatory …

Rheumatoid arthritis (RA), a multifactorial disease characterized by synovitis, cartilage
destruction, bone erosion, and periarticular decalcification, finally results in impairment of …

Ocular inflammatory disease is the third leading cause of blindness in the United States. In
addition to the conventional immunomodulatory agents, which include antimetabolites …

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic,
synovial inflammation affecting multiple joints, finally leading to extra‐articular lesions for …